



AUGUST SEMINAR NOTICE

Presented by
Yale School of Medicine's, Department of Therapeutic Radiology

“Dermatologic Toxicities from Systemic Cancer Therapy and Radiotherapy: Lessons Learned from Yale Onco-Dermatology Program”

Jonathan Leventhal, MD
Assistant Professor of Dermatology; Associate Director of Residency Program, Dermatology; Director of Onco-Dermatology Clinic; Department of Dermatology

Date: Thursday, August 26, 2021, 9:00AM
Location: Zoom Meeting

Course Director/Host: Henry S. Park, MD, MPH
There is no corporate support for this activity

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Attending Physicians; Housestaff/Fellows; Medical Students; Nurses; PA's; Other

NEEDS ASSESSMENT

Cutaneous toxicities to cancer therapy frequently occur from radiation and systemic oncologic therapies, and when severe can impact patients' quality of life and result in disruption of oncologic therapy. Therefore, recognition of common and uncommon cutaneous toxicities is important for medical oncologists and radiation oncologists caring for cancer patients.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Recognize cutaneous toxicities to systemic cancer therapies.
2. Recognize dermatologic complications of radiation therapy.
3. Diagnose, grade, and manage common dermatologic adverse events in cancer patients.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Jonathan Leventhal, MD – La Roche Posay, Honorarium-Advisory Board; Sanofi, Honorarium-Advisory Board; OnQuality, Research funding to Yale Univ-Principal Investigator; Azitra, Inc, Research funding to Yale Univ-Principal Investigator; Henry S. Park, MD, MPH – Bristol-Myers Squibb, Honorarium-Speaker

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.